We observed the expected patterns of genomic events in specific diagnoses, including TP53 rearrangements in osteosarcoma, EWSR1 rearrangements in Ewing sarcoma, ALK mutations and MYCN amplification in neuroblastoma, BRAF fusions and IDH1 mutations in low-grade glioma and TP53 mutations, CDKN2A/B deletions and H3F3A mutations in high-grade gliomas. This evidence concerns the gene CDKN2A and neuroblastoma.